Artivion Inc. (AORT)
29.71
0.37 (1.26%)
At close: Jan 14, 2025, 3:59 PM
29.26
-1.51%
Pre-market Jan 15, 2025, 04:09 AM EST
undefined% (undefined)
| Bid | 28.46 |
| Market Cap | 1.25B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.03 |
| PE Ratio (ttm) | -990.33 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 31.53 |
| Volume | 152,752 |
| Avg. Volume (20D) | 252,196 |
| Open | 29.42 |
| Previous Close | 29.34 |
| Day's Range | 29.14 - 29.75 |
| 52-Week Range | 16.48 - 30.45 |
| Beta | undefined |
About AORT
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems fo...
Industry Medical - Devices
Sector Healthcare
IPO Date Feb 12, 1993
Employees 1,500
Stock Exchange NYSE
Ticker Symbol AORT
Website https://artivion.com
Analyst Forecast
According to 5 analyst ratings, the average rating for AORT stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 7.71% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Artivion Inc. is scheduled to release its earnings on Feb 13, 2025,
during market hours.
Analysts project revenue of $101.15M, reflecting a 7.99% YoY growth and earnings per share of 0.04, making a -63.64% decrease YoY.
Analysts project revenue of $101.15M, reflecting a 7.99% YoY growth and earnings per share of 0.04, making a -63.64% decrease YoY.
8 months ago ·
Source
+12.81%
Artivion shares are trading higher after the compa...
Unlock content with
Pro Subscription
11 months ago ·
Source
+4.27%
Artivion shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY24 revenue guidance. Also, Needham maintained a Buy rating on the stock and raised its price target from $22 to $25.
